Low-dose TED-A9 cell therapy eases Parkinson’s motor symptoms

Three Parkinson’s patients treated with a low dose of TED-A9, an experimental stem cell therapy by S.Biomedics, showed improved motor symptoms after a year without side effects. In this small study, 12 adults who had Parkinson’s for over five years received a single brain transplant of TED-A9. The study tested both low and high doses of the therapy. The first three patients on the low dose had no complications and showed reduced motor symptoms after a year. Results from the high-dose group will be shared later this year. The study will end in 2026, with long-term safety monitoring. Parkinson’s is caused by the death of brain cells that produce dopamine, which controls movement. TED-A9 uses stem cells to create new dopamine-producing cells, implanted in the brain to replace those lost to the disease. In lab studies, TED-A9 successfully created new dopamine cells and improved symptoms in rats with Parkinson’s. In this study, the first three patients showed significant improvement in their movement scores and fewer symptoms despite stable medication use. The therapy appears to rebuild dopamine-producing cells, offering hope for a new treatment that directly addresses the root cause of Parkinson’s.